Literature DB >> 34562660

Tumor targeting and penetrating biomimetic mesoporous polydopamine nanoparticles facilitate photothermal killing and autophagy blocking for synergistic tumor ablation.

Xueqin Huang1, Lingzhi Chen2, Yongjian Lin2, Kai Ip Tou3, Huaihong Cai2, Hua Jin4, Wensen Lin4, Jianglin Zhang5, Jiye Cai6, Haibo Zhou7, Jiang Pi8.   

Abstract

The synergistic manipulation of autophagy blocking with tumor targeting and penetration effects to enhance cancer cell killing during photothermal therapy (PTT) remains a substantial challenge. Herein, we fabricated a biomimetic nanoplatform by precisely coating homologous prostate cancer cell membranes (CMs) onto the surface of mesoporous polydopamine nanoparticles (mPDA NPs) encapsulating the autophagy inhibitor chloroquine (CQ) for synergistically manipulating PTT and autophagy for anticancer treatment. The resulting biomimetic mPDA@CMs NPs-CQ system could escape macrophage phagocytosis, overcome the vascular barrier, and home in the homologous prostate tumor xenograft with high tumor targeting and penetrating efficiency. The mPDA NPs core endowed the mPDA@CMs NPs-CQ with good photothermal capability to mediate PTT killing of prostate cancer cells, while NIR-triggered CQ release from the nanosystem further arrested PTT-induced protective autophagy of cancer cells, thus weakening the resistance of prostate cancer cells to PTT. This combined PTT killing and autophagy blocking anticancer strategy could induce significant autophagosome accumulation, ROS generation, mitochondrial damage, endoplasmic reticulum stress, and apoptotic signal transduction, which finally results in synergistic prostate tumor ablation in vivo. This prostate cancer biomimetic nanosystem with synergistically enhanced anticancer efficiency achieved by manipulating PTT killing and autophagy blocking is expected to serve as a more effective anticancer strategy against prostate cancer. STATEMENT OF SIGNIFICANCE: Autophagy is considered as one of the most efficient rescuer and reinforcement mechanisms of cancer cells against photothermal therapy (PTT)-induced cancer cell eradication. How to synergistically manipulate autophagy blocking with significant tumor targeting and penetration to enhance PTT-mediated cancer cell killing remains a substantial challenge. Herein, we fabricated a biomimetic nanoplatform by precisely coating homologous cancer cell membranes onto the surface of mesoporous polydopamine nanoparticles with encapsulation of the autophagy inhibitor chloroquine for synergistic antitumor treatment with high tumor targeting and penetrating efficiency both in vitro and in vivo. This biomimetic nanosystem with synergistically enhanced anticancer efficiency by manipulating PTT killing and autophagy blocking is expected to serve as a more effective anticancer strategy.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Autophagy blocking; Biomimetic nanoplatform; Mesoporous polydopamine nanoparticles; Photothermal therapy; Synergistic anticancer effects

Mesh:

Substances:

Year:  2021        PMID: 34562660     DOI: 10.1016/j.actbio.2021.09.030

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  3 in total

Review 1.  Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics.

Authors:  Menglu Zhu; Yi Shi; Yifan Shan; Junyan Guo; Xuelong Song; Yuhua Wu; Miaolian Wu; Yan Lu; Wei Chen; Xiaoling Xu; Longguang Tang
Journal:  J Nanobiotechnology       Date:  2021-11-24       Impact factor: 10.435

2.  Toxicity Analysis of Mesoporous Polydopamine on Intestinal Tissue and Microflora.

Authors:  Luoyijun Xie; Qiyan Li; Yingying Liao; Zihua Huang; Yulin Liu; Chutong Liu; Leilei Shi; Qingjiao Li; Miaomiao Yuan
Journal:  Molecules       Date:  2022-09-30       Impact factor: 4.927

Review 3.  Advances and Potentials of Polydopamine Nanosystem in Photothermal-Based Antibacterial Infection Therapies.

Authors:  Shuhao Fan; Wensen Lin; Yifan Huang; Jiaojiao Xia; Jun-Fa Xu; Junai Zhang; Jiang Pi
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.